These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15800703)

  • 1. Progression of liver fibrosis in young blood donors infected with hepatitis C virus: different predictive factors?
    Vadan R; Gheorghe L
    Rom J Gastroenterol; 2005 Mar; 14(1):99-100; author reply 100. PubMed ID: 15800703
    [No Abstract]   [Full Text] [Related]  

  • 2. Progression of liver fibrosis in blood donors infected with hepatitis C virus.
    Silva GF; Coelho KI; Nishimura NF; Soares EC
    Rom J Gastroenterol; 2004 Dec; 13(4):291-7. PubMed ID: 15624026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection.
    Cross TJ; Quaglia A; Hughes S; Joshi D; Harrison PM
    J Viral Hepat; 2009 Jul; 16(7):492-9. PubMed ID: 19200134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of hepatic fibrosis progression in chronic hepatitis C virus infection in India.
    Hissar SS; Kumar M; Tyagi P; Goyal A; Suneetha PV; Agarwal S; Rastogi A; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2009 Apr; 24(4):581-7. PubMed ID: 19032460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C.
    Dinesen L; Caspary WF; Chapman RW; Dietrich CF; Sarrazin C; Braden B
    Dig Liver Dis; 2008 Sep; 40(9):743-8. PubMed ID: 18339592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.
    Leandro G; Mangia A; Hui J; Fabris P; Rubbia-Brandt L; Colloredo G; Adinolfi LE; Asselah T; Jonsson JR; Smedile A; Terrault N; Pazienza V; Giordani MT; Giostra E; Sonzogni A; Ruggiero G; Marcellin P; Powell EE; George J; Negro F;
    Gastroenterology; 2006 May; 130(6):1636-42. PubMed ID: 16697727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history and predictors of disease severity in chronic hepatitis C.
    Massard J; Ratziu V; Thabut D; Moussalli J; Lebray P; Benhamou Y; Poynard T
    J Hepatol; 2006; 44(1 Suppl):S19-24. PubMed ID: 16356583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients.
    Adinolfi LE; Ingrosso D; Cesaro G; Cimmino A; D'Antò M; Capasso R; Zappia V; Ruggiero G
    Hepatology; 2005 May; 41(5):995-1003. PubMed ID: 15834927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease.
    Masarone M; La Mura V; Bruno S; Gaeta GB; Vecchione R; Carrino F; Moschella F; Torella R; Persico M
    J Viral Hepat; 2007 Oct; 14(10):714-20. PubMed ID: 17875006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should trichrome stain be used on all post-liver transplant biopsies with hepatitis C virus infection to estimate the fibrosis score?
    Tretheway D; Jain A; LaPoint R; Sharma R; Orloff M; Milot P; Bozorgzadeh A; Ryan C
    Liver Transpl; 2008 May; 14(5):695-700. PubMed ID: 18324621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multivariable model of clinical variables predicts advanced fibrosis in chronic hepatitis C.
    Alsatie M; Kwo PY; Gingerich JR; Qi R; Eckert G; Cummings OW; Imperiale TF
    J Clin Gastroenterol; 2007 Apr; 41(4):416-21. PubMed ID: 17413613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease progression in Chinese chronic hepatitis C patients with persistently normal alanine aminotransaminase levels.
    Hui CK; Zhang HY; Shek T; Yao H; Yueng YH; Leung KW; Lai ST; Lai JY; Leung N; Lau GK
    Aliment Pharmacol Ther; 2007 Jun; 25(11):1283-92. PubMed ID: 17509096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation.
    de Arias AE; Haworth SE; Belli LS; Burra P; Pinzello G; Vangeli M; Minola E; Guido M; Boccagni P; De Feo TM; Torelli R; Cardillo M; Scalamogna M; Poli F
    Liver Transpl; 2009 Apr; 15(4):390-9. PubMed ID: 19326408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C.
    Vidali M; Occhino G; Ivaldi A; Rigamonti C; Sartori M; Albano E
    Am J Gastroenterol; 2008 Jan; 103(1):147-53. PubMed ID: 18184121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus and nonalcoholic Fatty liver disease: similar risk factors for necroinflammation, fibrosis, and cirrhosis.
    Comparcola D; Alisi A; Nobili V
    Clin Gastroenterol Hepatol; 2010 Jan; 8(1):97; author reply 97. PubMed ID: 19772950
    [No Abstract]   [Full Text] [Related]  

  • 16. Progression of liver fibrosis among injection drug users with chronic hepatitis C.
    Wilson LE; Torbenson M; Astemborski J; Faruki H; Spoler C; Rai R; Mehta S; Kirk GD; Nelson K; Afdhal N; Thomas DL
    Hepatology; 2006 Apr; 43(4):788-95. PubMed ID: 16557548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus.
    Kita Y; Mizukoshi E; Takamura T; Sakurai M; Takata Y; Arai K; Yamashita T; Nakamoto Y; Kaneko S
    Metabolism; 2007 Dec; 56(12):1682-8. PubMed ID: 17998021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation.
    Botha JF; Thompson E; Gilroy R; Grant WJ; Mukherjee S; Lyden ER; Fox IJ; Sudan DL; Shaw BW; Langnas AN
    Liver Int; 2007 Aug; 27(6):758-63. PubMed ID: 17617118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delta-S entropy variation system: a novel biophysical approach to treat chronic-degenerative processes. The challenge of liver cirrhosis.
    Marineo G; Marotta F
    Saudi Med J; 2004 Aug; 25(8):979-82. PubMed ID: 15322583
    [No Abstract]   [Full Text] [Related]  

  • 20. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.
    Selzner N; Girgrah N; Lilly L; Guindi M; Selzner M; Therapondos G; Adeyi O; McGilvray I; Cattral M; Greig PD; Grant D; Levy G; Renner EL
    Liver Transpl; 2008 Dec; 14(12):1778-86. PubMed ID: 19025914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.